X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (936) 936
hirudins - analogs & derivatives (639) 639
recombinant proteins - therapeutic use (446) 446
male (380) 380
hirudins - pharmacology (341) 341
animals (332) 332
hirudin (303) 303
hirudin therapy (303) 303
hematology (297) 297
anticoagulants - therapeutic use (288) 288
recombinant hirudin (283) 283
female (273) 273
thrombin - antagonists & inhibitors (272) 272
heparin (269) 269
peptide fragments - therapeutic use (256) 256
thrombin (239) 239
peripheral vascular disease (238) 238
heparin - adverse effects (217) 217
middle aged (216) 216
heparin - therapeutic use (202) 202
recombinant proteins - pharmacology (193) 193
cardiac & cardiovascular systems (192) 192
aged (185) 185
anticoagulants - adverse effects (174) 174
thrombocytopenia - chemically induced (173) 173
index medicus (171) 171
hirudins - administration & dosage (169) 169
anticoagulants (166) 166
amino acid sequence (159) 159
molecular sequence data (156) 156
fibrinolytic agents - therapeutic use (155) 155
peptide fragments - pharmacology (149) 149
recombinant proteins - administration & dosage (147) 147
thrombosis (140) 140
antithrombins - therapeutic use (139) 139
thrombin - metabolism (139) 139
biochemistry & molecular biology (123) 123
hirudins - chemistry (121) 121
pharmacology & pharmacy (119) 119
bivalirudin (118) 118
hirudins - adverse effects (118) 118
anticoagulants - pharmacology (117) 117
treatment outcome (117) 117
molecular-weight heparin (116) 116
anticoagulants - administration & dosage (115) 115
acute myocardial-infarction (112) 112
recombinant proteins - adverse effects (108) 108
adult (106) 106
heparin-induced thrombocytopenia (106) 106
platelet aggregation inhibitors - therapeutic use (102) 102
fibrinolytic agents - pharmacology (98) 98
dose-response relationship, drug (96) 96
partial thromboplastin time (95) 95
antithrombins - pharmacology (94) 94
thrombosis - prevention & control (89) 89
ticlopidine - analogs & derivatives (89) 89
angioplasty, balloon, coronary (88) 88
blood coagulation - drug effects (88) 88
drug therapy, combination (86) 86
unfractionated heparin (85) 85
rats (84) 84
cardiopulmonary bypass (83) 83
heparin - pharmacology (83) 83
peptide fragments - administration & dosage (83) 83
angioplasty (82) 82
thrombosis - drug therapy (82) 82
myocardial infarction - drug therapy (81) 81
hirudins - metabolism (79) 79
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (79) 79
binding sites (78) 78
anticoagulation (76) 76
kinetics (76) 76
hirudins (75) 75
anticoagulant (74) 74
inhibition (74) 74
clinical trials as topic (73) 73
percutaneous coronary intervention (73) 73
thrombin - chemistry (72) 72
hemorrhage - chemically induced (69) 69
human alpha-thrombin (69) 69
thrombocytopenia - drug therapy (69) 69
time factors (69) 69
peptide fragments - adverse effects (66) 66
platelet aggregation - drug effects (65) 65
surgery (64) 64
argatroban (63) 63
aspirin - therapeutic use (61) 61
drug therapy (61) 61
thrombolysis (61) 61
heparin - administration & dosage (60) 60
hirudins - pharmacokinetics (60) 60
protein conformation (60) 60
pipecolic acids - therapeutic use (58) 58
platelet aggregation inhibitors - pharmacology (57) 57
ticlopidine - therapeutic use (56) 56
prevention (55) 55
activation (54) 54
cardiology (54) 54
peptide fragments - chemistry (54) 54
unstable angina (54) 54
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1177) 1177
French (23) 23
German (23) 23
Russian (5) 5
Spanish (4) 4
Chinese (3) 3
Japanese (2) 2
Polish (2) 2
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bioorganicheskaia khimiia, ISSN 0132-3423, 03/2012, Volume 38, Issue 2, p. 166
Journal Article
Research in Pharmaceutical Sciences, ISSN 1735-5362, 02/2017, Volume 12, Issue 1, pp. 60 - 66
Hirudin is an anticoagulant agent of the salivary glands of the medicinal leech. Recombinant hirudin (r-Hir) displays certain drawbacks including bleeding and... 
In silico | PEGylation | Hirudin variant 3 | Cysteine | Anticoagulants (Medicine) | Cystine | Original
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
Mortality and morbidity in acute coronary syndromes (ACSs), caused principally by plaque erosion or rupture leading to thrombus formation and myocardial... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Circulation, ISSN 0009-7322, 08/2004, Volume 110, Issue 8, pp. 994 - 998
Background - Unfractionated heparin (UFH) is the most widely used antithrombin during percutaneous coronary intervention (PCI). Despite significant... 
Heparin | Ischemia | Angioplasty | Hemorrhage | REVASCULARIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | LOW-DOSE HEPARIN | GLYCOPROTEIN IIB/IIIA RECEPTOR | ABCIXIMAB | TIROFIBAN | ischemia | ANTICOAGULATION | heparin | BIVALIRUDIN | PERIPHERAL VASCULAR DISEASE | BLOCKADE | HEMATOLOGY | angioplasty | hemorrhage | UNFRACTIONATED HEPARIN | Hirudins - analogs & derivatives | Recombinant Proteins - therapeutic use | Myocardial Infarction - epidemiology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Heparin - adverse effects | Tyrosine - analogs & derivatives | Hirudins - administration & dosage | Angioplasty, Balloon, Coronary | Incidence | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Tyrosine - adverse effects | Aspirin - therapeutic use | Myocardial Infarction - etiology | Platelet Aggregation Inhibitors - adverse effects | Comorbidity | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Drug Synergism | Coronary Restenosis - epidemiology | Blood Coagulation Tests | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Anticoagulants - administration & dosage | Ticlopidine - therapeutic use | Immunoglobulin Fab Fragments - adverse effects | Antibodies, Monoclonal - adverse effects | Heparin - administration & dosage | Heparin - therapeutic use | Recombinant Proteins - adverse effects | Aspirin - administration & dosage | Multicenter Studies as Topic | Tyrosine - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Female | Myocardial Ischemia - mortality | Retrospective Studies | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Stents | Thrombophilia - drug therapy | Myocardial Ischemia - epidemiology | Double-Blind Method | Hemorrhage - epidemiology | Peptide Fragments - administration & dosage | Recombinant Proteins - administration & dosage | Randomized Controlled Trials as Topic | Immunoglobulin Fab Fragments - administration & dosage | Myocardial Ischemia - etiology | Antibodies, Monoclonal - administration & dosage | Hirudins - adverse effects | Aged | Tyrosine - administration & dosage
Journal Article
JAMA, ISSN 0098-7484, 04/2015, Volume 313, Issue 13, pp. 1336 - 1346
Journal Article
Chest, ISSN 0012-3692, 2004, Volume 126, Issue 3, pp. 576S - 599S
This chapter about antithrombotic therapy during percutaneous coronary intervention (PCI) is part of the seventh ACCP Conference on Antithrombotic and... 
Anticoagulation | Percutaneous coronary intervention | Stent | Unstable angina | Prophylaxis | stent | ACTIVATED CLOTTING TIMES | LOW-DOSE HEPARIN | anticoagulation | PLATELET GLYCOPROTEIN-IIB/IIIA | RANDOMIZED CONTROLLED-TRIAL | prophylaxis | SIROLIMUS-ELUTING STENTS | percutaneous coronary intervention | RESPIRATORY SYSTEM | MOLECULAR-WEIGHT HEPARIN | ACUTE MYOCARDIAL-INFARCTION | unstable angina | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | UNSTABLE ANGINA-PECTORIS | CRITICAL CARE MEDICINE | Hirudins - analogs & derivatives | Recombinant Proteins - therapeutic use | Ticlopidine - therapeutic use | Humans | Immunoglobulin Fab Fragments - adverse effects | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary | Contraindications | Fibrinolytic Agents - adverse effects | Pyridines - adverse effects | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Drug Therapy, Combination | Stents | Pyridines - therapeutic use | Coronary Stenosis - therapy | Risk Assessment | Coronary Restenosis - prevention & control | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Hirudins - adverse effects | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Practice Guidelines as Topic
Journal Article
European Heart Journal, ISSN 0195-668X, 2014, Volume 35, Issue 34, pp. 2285 - 2294
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 03/2015, Volume 8, Issue 3, pp. 424 - 433
Objectives The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing... 
CHAMPION PHOENIX | cangrelor | bivalirudin | stent thrombosis | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | TICAGRELOR | PREDICTORS | PLATELET INHIBITION | PRASUGREL | ELEVATION MYOCARDIAL-INFARCTION | Recombinant Proteins - therapeutic use | Ticlopidine - therapeutic use | Percutaneous Coronary Intervention - mortality | Humans | Middle Aged | Male | Recombinant Proteins - adverse effects | Percutaneous Coronary Intervention - instrumentation | Time Factors | Coronary Thrombosis - prevention & control | Ticlopidine - adverse effects | Female | Odds Ratio | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Stents | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Treatment Outcome | Coronary Artery Disease - mortality | Anticoagulants - adverse effects | Chi-Square Distribution | Adenosine Monophosphate - therapeutic use | Ticlopidine - analogs & derivatives | Adenosine Monophosphate - adverse effects | Coronary Artery Disease - therapy | Coronary Artery Disease - diagnosis | Adenosine Monophosphate - analogs & derivatives | Hirudins - adverse effects | Aged | Coronary Thrombosis - etiology | Myocardial Infarction - prevention & control | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Percutaneous Coronary Intervention - adverse effects
Journal Article
The Lancet, ISSN 0140-6736, 01/2002, Volume 359, Issue 9303, pp. 294 - 302
To obtain more reliable and precise estimates of the effect of direct thrombin inhibitors in the management of acute coronary syndromes, including patients... 
MEDICINE, GENERAL & INTERNAL | THERAPY | SAFETY | ACUTE MYOCARDIAL-INFARCTION | HIRUDIN | THROMBOLYSIS | AGENTS | TERM | HEPARIN | HIRULOG | ARTERY-DISEASE | Hirudins - analogs & derivatives | Recombinant Proteins - therapeutic use | Glycine - analogs & derivatives | Glycine - therapeutic use | Myocardial Infarction - mortality | Antithrombins - therapeutic use | Humans | Thrombin - antagonists & inhibitors | Angina, Unstable - mortality | Heparin - therapeutic use | Survival Rate | Hirudin Therapy | Oligopeptides - therapeutic use | Randomized Controlled Trials as Topic | Myocardial Infarction - drug therapy | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Pipecolic Acids - therapeutic use | Peptide Fragments - therapeutic use | Dosage and administration | Enzyme inhibitors | Research | Drug therapy | Coronary heart disease | Prevention | Evaluation | Thrombin | Heparin | Thrombosis | Heart attack | Risk factors | Hirudin | Clinical trials | Cardiovascular disease | Heart attacks | Clinical outcomes | Myocardial infarction | Disorders | Argatroban | Hemorrhage | Bleeding | Subgroups | Reduction | Randomization | Scholarships & fellowships | Electrocardiography | Thromboembolism | Stroke | Statistical analysis | Mortality | Angina pectoris | Patients | Blood clots | Inhibitors | Collaboration | Death | Infarction | Acute coronary syndromes | Methods
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 05/2016, Volume 9, Issue 10, pp. 1036 - 1046
Objectives The study sought to compare the clinical efficacy and safety of P2Y inhibitors in patients with ST-segment elevation myocardial infarction (STEMI)... 
clopidogrel | inhibitors | percutaneous coronary intervention | prasugrel | P2Y | ticagrelor | ST-segment elevation myocardial infarction | thienopyridines | angioplasty | Recombinant Proteins - therapeutic use | Coronary Thrombosis - diagnosis | Markov Chains | Ticlopidine - therapeutic use | Hirudins | Percutaneous Coronary Intervention - mortality | Humans | Receptors, Purinergic P2Y12 - drug effects | ST Elevation Myocardial Infarction - diagnosis | ST Elevation Myocardial Infarction - blood | ST Elevation Myocardial Infarction - therapy | Purinergic P2Y Receptor Antagonists - adverse effects | Percutaneous Coronary Intervention - instrumentation | Receptors, Purinergic P2Y12 - blood | Adenosine - therapeutic use | Coronary Thrombosis - prevention & control | Network Meta-Analysis | Blood Platelets - drug effects | Odds Ratio | Platelet Aggregation Inhibitors - therapeutic use | Coronary Thrombosis - blood | Purinergic P2Y Receptor Antagonists - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Antithrombins - therapeutic use | Risk Factors | Treatment Outcome | Clinical Trials as Topic | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Prasugrel Hydrochloride - therapeutic use | ST Elevation Myocardial Infarction - mortality | Blood Platelets - metabolism | Adenosine - analogs & derivatives | Bayes Theorem | Coronary Thrombosis - etiology | Peptide Fragments - therapeutic use | Monte Carlo Method | Percutaneous Coronary Intervention - adverse effects
Journal Article
Circulation, ISSN 0009-7322, 04/2011, Volume 123, Issue 16, pp. 1745 - 1756
Background-Concerns persist regarding the risk of stent thrombosis in the setting of primary percutaneous coronary intervention for ST-segment elevation... 
stents | thrombosis | myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | RANDOMIZED-TRIALS | BARE-METAL STENTS | ROUTINE CLINICAL-PRACTICE | UNCOATED STENTS | CLOPIDOGREL | IMPLANTATION | LARGE 2-INSTITUTIONAL COHORT | PLATELET INHIBITION | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | DRUG-ELUTING STENTS | Recombinant Proteins - therapeutic use | Predictive Value of Tests | Myocardial Infarction - epidemiology | Coronary Thrombosis - epidemiology | Ticlopidine - therapeutic use | Hirudins | Humans | Metals | Middle Aged | Heparin - therapeutic use | Male | Angioplasty, Balloon, Coronary - statistics & numerical data | Drug-Eluting Stents - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Myocardial Infarction - therapy | Coronary Thrombosis - prevention & control | Drug-Eluting Stents - statistics & numerical data | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Antithrombins - therapeutic use | Risk Factors | Anticoagulants - therapeutic use | Coronary Restenosis - prevention & control | Treatment Outcome | Paclitaxel - therapeutic use | Ticlopidine - analogs & derivatives | Tubulin Modulators - therapeutic use | Coronary Restenosis - epidemiology | Aged | Peptide Fragments - therapeutic use | Complications and side effects | Care and treatment | Angioplasty | Research | Thrombosis | Heart attack | Stent (Surgery) | Blood clot | Risk factors
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2011, Volume 58, Issue 22, pp. 2263 - 2269
Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with... 
Cardiovascular | Internal Medicine | non–ST-segment elevation myocardial infarction | chronic kidney disease | bleeding | ST-segment elevation myocardial infarction | unstable angina | acute coronary syndrome(s) | antiplatelet | antithrombotic | nonST-segment elevation myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | WAVE MYOCARDIAL-INFARCTION | HIGH-RISK PATIENTS | GLYCOPROTEIN IIB/IIIA INHIBITORS | non-ST-segment elevation myocardial infarction | MOLECULAR-WEIGHT HEPARIN | PLATELET INHIBITION | DOUBLE-BLIND | ST-SEGMENT ELEVATION | STAGE RENAL-DISEASE | UNFRACTIONATED HEPARIN | ARTERY-DISEASE | Piperazines - administration & dosage | Prasugrel Hydrochloride | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Heparin - administration & dosage | Thiophenes - administration & dosage | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Aspirin - administration & dosage | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Acute Coronary Syndrome - complications | Aspirin - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Polysaccharides - administration & dosage | Kidney Diseases - complications | Platelet Aggregation Inhibitors - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Clinical Trials as Topic | Uremia - complications | Adenosine - administration & dosage | Piperazines - adverse effects | Recombinant Proteins - administration & dosage | Ticlopidine - analogs & derivatives | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Hemorrhage - chemically induced | Chronic Disease | Care and treatment | Chronic kidney failure | Cardiac patients | Cardiology | Coronary heart disease | Health aspects | Cardiovascular agents | Medical colleges | Mortality | Heart attacks | Drug therapy | Acute coronary syndromes | Coronary vessels
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2008, Volume 359, Issue 7, pp. 688 - 696
Journal Article